In 2015, the chairman of Sun Pharma Dilip Shanghvi had briefly dethroned Mukesh Ambani to become the country’s richest man. His response to that was, “I am not comfortable.” Though he doesn ...
Dilip Shanghvi's journey from the beginning with just Rs 2,000 highlights the importance of resilience, adaptability, and ...
Sun Pharmaceutical Industries officials, including CMD Dilip Shanghvi, were fined by the Ministry of Corporate Affairs for ...
Newsable Asianet News on MSN3d
Dhirubhai Ambani to Gautam Adani: What were the first jobs of India's billionaires?Discover the surprising first jobs of India's leading billionaires, including Mukesh Ambani, Gautam Adani, Savitri Jindal, ...
Sun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to ...
For any ordinary man, it would mean continuing to run the father’s wholesale medicine shop, and living a contented, financially stable yet unremarkable life. But Dilip Shanghvi, 67, is no ...
In January 2018, the Indian government appointed Shanghvi to the Reserve Bank of India's 21-member central board committee. He was awarded Padma Shri in 2016 by the Government of India.
Sharing details of Sun Pharma's mergers and acquisitions (M&As) and strategic partnerships, Dilip Shanghvi said, "We are currently in the process of integrating Concert Pharmaceuticals that we ...
But Sun remains India's most valuable drug company (recent market cap: $30.5 billion). Shanghvi personally paid $270 million for a 23% stake in struggling wind-power firm Suzlon Energy in February ...
Dilip Shanghvi, promoter and Managing Director of Sun Pharmaceutical Industries (Sun Pharma), forewent 99 percent of his FY19 salary as India’s largest drug maker optimised operational costs due ...
Dilip Shanghvi, Subhash Chandra want a slice of oil block action India‘s top pharma and media barons are lining up to have a fill of the country‘s oil blocks. Sun Pharma founder Dilip Shanghvi ...
India's richest pharma magnate's wealth is down by $1.1 billion along with a drop in shares of his Sun Pharmaceutical Industries, the world's fifth-largest generics maker. The company's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback